Prevalence and Reactivation of Hepatitis B and C in Patients Undergoing Chemotherapy for Solid Tumors - PubMed
7 hours ago
- #Chemotherapy
- #Viral Reactivation
- #Hepatitis B
- Hepatitis B (HBV) and C (HCV) infections are significant in cancer patients due to chemotherapy-induced viral reactivation risks.
- A retrospective study in Turkey analyzed 15,942 adults with solid tumors receiving chemotherapy (2018-2022).
- HBV screening (HBsAg) was performed in 90.3% of patients, HCV (anti-HCV) in 71.7%, and HIV in 64.0%.
- HBV infection prevalence was 4.5%, with only 42.9% receiving antiviral prophylaxis; reactivation occurred in 4.0% of HBsAg-positive cases.
- HCV prevalence was 0.4%, with 17.4% having detectable RNA and receiving treatment; HIV was rare (0.06%) with no reactivation.
- The study underscores gaps in screening and prophylaxis, advocating for standardized protocols to prevent complications.